Syros Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing innovative medicines that control gene expression. With a focus on the discovery and development of novel gene control therapies, Syros is at the forefront of a new wave of treatments aimed at addressing diseases with high unmet medical needs.
Company Overview
Pro stress-test →Syros Pharmaceuticals, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts. The company utilizes its proprietary gene control platform to identify and drug novel targets linked to genomically defined diseases. Syros’ mission is to transform patients’ lives through the creation of treatments that are not only effective but also specific to the underlying mechanisms of their diseases.
Product Portfolio
Pro stress-test →Syros Pharmaceuticals’ product portfolio is predominantly focused on oncology and monogenic diseases. Their lead product candidates include:
- SY-1425: A selective retinoic acid receptor alpha (RARα) agonist for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
- SY-5609: A highly selective and potent oral CDK7 inhibitor for solid tumors, including breast, colorectal, and lung cancers.
- SY-2101: An oral form of arsenic trioxide for patients with acute promyelocytic leukemia (APL).
Leadership and Management Team
Pro stress-test →Syros Pharmaceuticals is led by a team of seasoned professionals who bring extensive experience in drug discovery, development, and commercialization:
- Nancy Simonian, M.D.: Chief Executive Officer
- David A. Roth, M.D.: Chief Medical Officer
- Kristin Stephens: Chief Development Officer
Financial Overview of Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc. has shown a strong financial stance with a focus on strategic investments in their research and development programs. Key financial metrics include:
- Revenue: $15 million (2022)
- Research and Development Expenses: $75 million (2022)
- Cash and Cash Equivalents: $100 million (2022)
Marketing Strategies
Syros Pharmaceuticals employs a targeted marketing strategy focused on building awareness among healthcare professionals, investors, and patients. They leverage scientific publications, conferences, and digital marketing to communicate their progress and innovations.
Syros Pharmaceuticals, Inc. Market Research and Competitors
Syros operates in a highly competitive biopharmaceutical market. Key competitors include companies like Gilead Sciences, Bristol-Myers Squibb, and Novartis. Despite the competition, Syros differentiates itself through its unique gene control platform and targeted approach to drug development.
Sales Strategies
Syros Pharmaceuticals has yet to commercialize its products as they are still in clinical development. Their sales strategies will likely involve partnerships with larger pharmaceutical companies and direct sales to healthcare institutions upon regulatory approval.
Technologies Utilized
Key technologies and innovations at Syros Pharmaceuticals include:
- Gene Control Platform: Proprietary technology for identifying and drugging novel genomic targets.
- CDK7 Inhibition: Targeting cyclin-dependent kinase 7 to halt cancer cell proliferation.
HR Practices
Syros Pharmaceuticals is committed to fostering a collaborative and inclusive work environment. They emphasize professional development, diversity, and employee well-being as core components of their HR practices.
Corporate Responsibility
Syros Pharmaceuticals is dedicated to corporate social responsibility, focusing on ethical research practices, community engagement, and environmental sustainability. They actively participate in initiatives that support patient communities and scientific education.
Future Plans
Looking ahead, Syros Pharmaceuticals plans to advance its clinical programs, expand its gene control platform, and explore strategic partnerships to bring its innovative therapies to market. They are committed to addressing unmet medical needs and improving patient outcomes globally.
Get the complete report on Syros Pharmaceuticals, Inc. by subscribing to our service